TY - JOUR
T1 - Next generation metronomic chemotherapy - Report from the fifth Biennial International Metronomic and Anti-Angiogenic Therapy meeting, 6-8 May 2016, Mumbai
AU - Pantziarka, Pan
AU - Hutchinson, Lisa
AU - André, Nicolas
AU - Benzekry, Sébastien
AU - Bertolini, Francesco
AU - Bhattacharjee, Atanu
AU - Chiplunkar, Shubhada
AU - Duda, Dan G.
AU - Gota, Vikram
AU - Gupta, Sudeep
AU - Joshi, Amit
AU - Kannan, Sadhana
AU - Kerbel, Robert
AU - Kieran, Mark
AU - Palazzo, Antonella
AU - Parikh, Aparna
AU - Pasquier, Eddy
AU - Patil, Vijay
AU - Prabhash, Kumar
AU - Shaked, Yuval
AU - Sholler, Giselle Saulnier
AU - Sterba, Jaroslav
AU - Waxman, David J.
AU - Banavali, Shripad
N1 - Publisher Copyright:
© 2016 the authors.
PY - 2016/11/2
Y1 - 2016/11/2
N2 - The 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th - 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and predictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.
AB - The 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th - 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and predictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.
UR - http://www.scopus.com/inward/record.url?scp=84996559005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996559005&partnerID=8YFLogxK
U2 - 10.3332/ecancer.2016.689
DO - 10.3332/ecancer.2016.689
M3 - Article
AN - SCOPUS:84996559005
SN - 1754-6605
VL - 10
JO - ecancermedicalscience
JF - ecancermedicalscience
M1 - 689
ER -